ArticleJournal of gastrointestinal oncology2026

Erratum: Efficacy and safety of dose adjustment for fruquintinib in the third-line treatment of metastatic colorectal cancer: a retrospective study with real-world settings.

No numbers read from the abstract.

Not cited yet